These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Design and Use of Chikungunya Virus Replication Templates Utilizing Mammalian and Mosquito RNA Polymerase I-Mediated Transcription. Utt A; Rausalu K; Jakobson M; Männik A; Alphey L; Fragkoudis R; Merits A J Virol; 2019 Sep; 93(18):. PubMed ID: 31217251 [TBL] [Abstract][Full Text] [Related]
8. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design. Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S mBio; 2017 Feb; 8(1):. PubMed ID: 28223458 [TBL] [Abstract][Full Text] [Related]
9. 4'-Fluorouridine inhibits alphavirus replication and infection Yin P; May NA; Lello LS; Fayed A; Parks MG; Drobish AM; Wang S; Andrews M; Sticher Z; Kolykhalov AA; Natchus MG; Painter GR; Merits A; Kielian M; Morrison TE mBio; 2024 Jun; 15(6):e0042024. PubMed ID: 38700353 [TBL] [Abstract][Full Text] [Related]
10. Using SHAPE-MaP To Model RNA Secondary Structure and Identify 3'UTR Variation in Chikungunya Virus. Madden EA; Plante KS; Morrison CR; Kutchko KM; Sanders W; Long KM; Taft-Benz S; Cruz Cisneros MC; White AM; Sarkar S; Reynolds G; Vincent HA; Laederach A; Moorman NJ; Heise MT J Virol; 2020 Nov; 94(24):. PubMed ID: 32999019 [TBL] [Abstract][Full Text] [Related]
11. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346 [TBL] [Abstract][Full Text] [Related]
13. Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates. Akhrymuk I; Lukash T; Frolov I; Frolova EI J Virol; 2019 Feb; 93(4):. PubMed ID: 30487275 [TBL] [Abstract][Full Text] [Related]
14. Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway. Bouma EM; van de Pol DPI; Sanders ID; Rodenhuis-Zybert IA; Smit JM J Virol; 2020 Jun; 94(13):. PubMed ID: 32321803 [TBL] [Abstract][Full Text] [Related]
15. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. Rothan HA; Bahrani H; Abdulrahman AY; Mohamed Z; Teoh TC; Othman S; Rashid NN; Rahman NA; Yusof R Antiviral Res; 2016 Mar; 127():50-6. PubMed ID: 26794398 [TBL] [Abstract][Full Text] [Related]
16. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation. Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436 [TBL] [Abstract][Full Text] [Related]
17. G3BP/Rin-Binding Motifs Inserted into Flexible Regions of nsP2 Support RNA Replication of Chikungunya Virus. Wang S; Merits A J Virol; 2022 Nov; 96(21):e0127822. PubMed ID: 36226983 [TBL] [Abstract][Full Text] [Related]
18. Multiple Host Factors Interact with the Hypervariable Domain of Chikungunya Virus nsP3 and Determine Viral Replication in Cell-Specific Mode. Meshram CD; Agback P; Shiliaev N; Urakova N; Mobley JA; Agback T; Frolova EI; Frolov I J Virol; 2018 Aug; 92(16):. PubMed ID: 29899097 [TBL] [Abstract][Full Text] [Related]